ondansetron has been researched along with Carcinoma, Non-Small Cell Lung in 5 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study is to compare the effectiveness of olanzapine combined with ondansetron or ondansetron alone in preventing chemotherapy-induced nausea and vomiting (CINV) of non-small cell lung cancer (NSCLC)." | 9.20 | Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer. ( Wang, H; Wang, L; Wang, X; Zhang, H, 2015) |
| "Palonosetron is a highly potent second-generation selective 5-HT3 receptor antagonist with stronger binding affinity for the 5-HT3 receptor." | 6.76 | Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients. ( Cao, R; Dong, X; Huang, J; Liu, L, 2011) |
| "The objective of this study is to compare the effectiveness of olanzapine combined with ondansetron or ondansetron alone in preventing chemotherapy-induced nausea and vomiting (CINV) of non-small cell lung cancer (NSCLC)." | 5.20 | Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer. ( Wang, H; Wang, L; Wang, X; Zhang, H, 2015) |
| "Palonosetron is a highly potent second-generation selective 5-HT3 receptor antagonist with stronger binding affinity for the 5-HT3 receptor." | 2.76 | Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients. ( Cao, R; Dong, X; Huang, J; Liu, L, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, X | 1 |
| Wang, L | 1 |
| Wang, H | 1 |
| Zhang, H | 1 |
| Suzuki, S | 1 |
| Karayama, M | 1 |
| Inui, N | 1 |
| Kuroishi, S | 1 |
| Fujisawa, T | 1 |
| Enomoto, N | 1 |
| Nakamura, Y | 1 |
| Yokomura, K | 1 |
| Toyoshima, M | 1 |
| Imokawa, S | 1 |
| Asada, K | 1 |
| Masuda, M | 1 |
| Yamada, T | 1 |
| Watanabe, H | 1 |
| Hayakawa, H | 1 |
| Suda, T | 1 |
| Dong, X | 1 |
| Huang, J | 1 |
| Cao, R | 1 |
| Liu, L | 1 |
| Kosmidis, PA | 1 |
| Kalofonos, HP | 1 |
| Christodoulou, C | 1 |
| Syrigos, K | 1 |
| Makatsoris, T | 1 |
| Skarlos, D | 1 |
| Bakogiannis, C | 1 |
| Nicolaides, C | 1 |
| Bafaloukos, D | 1 |
| Bamias, A | 1 |
| Samantas, E | 1 |
| Xiros, N | 1 |
| Boukovinas, I | 1 |
| Fountzilas, G | 1 |
| Dimopoulos, MA | 1 |
| Tsavaris, N | 1 |
| Kosmas, CH | 1 |
| Vadiaka, M | 1 |
| Kontos, A | 1 |
| Katsorida, M | 1 |
| Dimitrakopoulos, A | 1 |
| Zerai, A | 1 |
| Koufos, CH | 1 |
5 trials available for ondansetron and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Benzodiazepines; Carcinoma, Non-Small-Cell Lung; Dr | 2015 |
Sequential addition of aprepitant in patients receiving carboplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Bevacizumab; Carbopl | 2016 |
Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Iso | 2011 |
Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2008 |
Efficacy of ondansentron treatment for acute emesis with different dosing schedules 8 vs 32 mg. A randomized study.
Topics: Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2001 |